Clinical Trial

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Recruiting
View on ClinicalTrials.gov →
Summary
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Trial Details
NCT Number NCT07632677
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Fudan University, The First Affiliated Hospital of Soochow University, Xuzhou Central Hospital, First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Bengbu Medical University, The Second Hospital of Anhui Medical University, The Affiliated Hospital of Qingdao University, Weifang People's Hospital, Panyu Hospital of Traditional Chinese Medicine, Southern Medical University, China, First Affiliated Hospital of Guangxi Medical University, Zunyi Medical College, The First Affiliated Hospital of Air Force Medicial University, Hainan General Hospital, The Third People's Hospital of Yunnan Province, Sir Run Run Shaw Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Eighth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Wannan Medical College, Renmin Hospital of Wuhan University, The First Affiliated Hospital of University of South China
Conditions Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
Enrollment 10,000 participants
Start Date 2026-05-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-08